[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma.

Sarah R Verhoeff,Sjoukje F Oosting,Sjoerd G Elias,Suzanne C van Es, Sophie L Gerritse,Lindsay Angus,Sandra Heskamp,Ingrid M E Desar,C Willemien Menke-van der Houven van Oordt,Astrid A M van der Veldt,Anne I J Arens,Adrienne H Brouwers, Bertha Eisses,Peter F A Mulders,Otto S Hoekstra,Gerben J C Zwezerijnen,Winette T A van der Graaf,Erik H J G Aarntzen,Wim J G Oyen,Carla M L van Herpen

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 2|浏览44

暂无评分

摘要

In patients with good- or intermediate-risk mccRCC, low [18F]FDG uptake is associated with prolonged WW. This study shows the predictive value of the "W&W criteria" for WW duration and shows the potential of [18F]FDG-PET/CT to further improve this.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要